You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
The Development and Systematic Evaluation of an AI-Assisted Just-in-Time-Adaptive-Intervention for Improving Child Mental Health
SBC: Colliga Apps Corp. Topic: 104PROJECT SUMMARY/ABSTRACT Early childhood mental health problems constitute a significant public health concern with wide-ranging impacts on functioning both concurrently and later in life. Although childhood mental health is influenced by a variety of factors, the quality of relationships with caregivers plays a critical role. Critical, coercive, and conflictual parent- child interactions have bee ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Real-time Multimodal Diffuse Reflectance and Polarization Imaging Based Nerve Identification in Surgical Field of View
SBC: YAYA SCIENTIFIC LLC Topic: NIBIBPROJECT SUMMARY We propose to develop a novel non-contact, label-free multimodality imager that provides real-time intraoperative identification of nerves within the surgical field-of-view to facilitate the prevention of unintended nerve damage (termed iatrogenic nerve injury) during surgical procedures, as they are a major source of postsurgical complications, e.g., chronic pain. In the United St ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Cerenkov Multi-Spectral Imaging (CMSI) for Adaptation and Real-Time Imaging in Radiotherapy
SBC: ENDECTRA LLC Topic: 102PROJECT SUMMARY Understanding of tumor molecular characteristics during a course of radiotherapy (RT) treatment is crucial to assess the efficacy of the treatment and adapt radiation dosage to optimize outcomes. Unfortunately, this cannot be routinely achieved by current diagnostic nuclear imaging modalities due to complex logistics and prohibitive costs. Alternatively, Cerenkov Emission (CE) is a ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Photo-mediated ultrasound therapy for treatment of cutaneous vascular malformations
SBC: PHOTOSONOX LLC Topic: NIBIBABSTRACT: Cutaneous vascular malformations (CVM), such as port wine stain (PWS) which occurs in 0.3–0.5% of newborns, are often a cause of great concern to patients for both medical and cosmetic reasons. Laser irradiation with flashlamp-pumped pulsed dye lasers, i.e. photothermolysis therapy (PTT), is currently the gold standard treatment for PWS. Most patients with PWS, however, fail to clear c ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
RememberStuff: a dyadic-focused technology to support persons with Alzheimer's disease in the community
SBC: EPERTURE LLC Topic: NIAProject Abstract An estimated 5.7 million Americans have Alzheimer’s disease or a related dementia (ADRD) and one in ten people age 65 or older show symptoms of Alzheimer’s disease. As ADRD progresses so does the level of dependency on others. As the disease progresses, higher levels of dependence in people with Alzheimer’s disease are associated with significantly increased burden and costs ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Simple, low cost assay for detection of HIV-1 antiretroviral resistance in resource-limited settings
SBC: Discidium Biosciences, LLC Topic: NIAIDAntiretroviral therapy has become a reality in resource limited settings thanks to entities such as PEFAR and the Global Fund However contrary to the therapeutic choice flexibility in developed countries all patients go on reverse transcriptase inhibitor RTI based first line regimens with more expensive protease and integrase inhibitor based regimens being reserved as second line therapy for ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing high throughput measurement of thiopurine in DNA by mass spectrometry
SBC: TYMORA ANALYTICAL OPERATIONS LLC Topic: 400PROJECT SUMMARY Thiopurines such as mercaptopurine are S-substituted antimetabolites used as functional analogs to natural nucleobase precursors. They are highly effective against hematologic malignancies (leukemia and lymphoma) and autoimmune diseases (inflammatory bowel diseases [IBD]), with an estimated patient population andgt;350,000 in the US. However, the cytotoxicity of thiopurines depends ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Biodegradability and Biocompatibility of a Shape Memory Polymer Wrap to Improve Saphenous Vein Graft Patency in Peripheral and Coronary Artery Bypass Grafting Surgeries
SBC: VenoStent, Inc. Topic: NHLBIPROJECT SUMMARY/ABSTRACT Peripheral artery disease (PAD) affects nearly 12 million people in the United States. One of the most common surgical therapies is peripheral artery bypass grafting (PABG). Some patients are eligible for less invasive treatment options like angioplasty, but patients with calcified lesions are not. In patients that do receive PABG, approximately 20% fail within the first y ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?
SBC: Mabloc, LLC Topic: NIAIDPROJECT SUMMARY/ABSTRACT The recent groundbreaking experiment using a single neutralizing monoclonal antibody (nmAb) to reduce the death rate in Ebola virus (EBOV)-infected individuals highlights the importance of this class of drug in the treatment of infectious disease. In August 2019, Dr. Anthony Fauci announced that administration of mAb114 had reduced the death rate from 70% to approximately ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of Optimized AAV Serotype Vectors for Human Gene Therapy
SBC: Medosome Biotec, LLC Topic: NIAIDDESCRIPTION provided by applicant Adeno associated virus AAV is a non pathogenic human parvovirus and recombinant AAV vectors have gained significant attention owing to their safety and in some cases clinical efficacy in a number of Phase I II clinical trials However relatively large vector doses are needed to achieve clinical efficacy and such high doses can lead to host immune respon ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health